Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: A multicenter study in Argentina

Journal of Clinical Immunology

Volumn 33, Issue 7, 2013, Pages 1216-1222

  Bezrodnik, Liliana ^a   Gómez Raccio, Andrea ^a   Belardinelli, Gabriela ^a   Regairaz, Lorena ^a,b   Díaz Ballve, Damacia ^a   Seminario, Gisela ^a   Moreira, Ileana ^a   Riganti, Carlos ^c   Cantisano, Claudio ^c   Díaz, Héctor ^c   Di Giovanni, Daniela ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b Hospital de Ninos Sor Maria Ludovica   (Argentina)

^c HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

Author keywords

Argentina; Beriglobina P; children; immunoglobulin therapy; intravenous; primary immunodeficiency; subcutaneous

Indexed keywords

HUMAN IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ARGENTINA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RATE; INFUSION RELATED REACTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCHOOL CHILD; SEVERE COMBINED IMMUNODEFICIENCY; X LINKED AGAMMAGLOBULINEMIA;

ADOLESCENT; ARGENTINA; CHILD; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOTHERAPY; INFECTION; INJECTIONS, SUBCUTANEOUS; MALE; PROSPECTIVE STUDIES;

EID: 84885182424     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-013-9916-z     Document Type: Article

References (32)

1. Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, Conley ME, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124(6):1161-78. doi: 10.1016/j.jaci.2009.10.013.
2. Borte S, Janzi M, Pan-Hammarstrom Q, von Dobeln U, Nordvall L, Winiarski J, et al. Placental transfer of maternally-derived IgA precludes the use of guthrie card eluates as a screening tool for primary immunodeficiency diseases. PLoS One. 2012;7(8):e43419. doi: 10.1371/journal.pone.0043419.
3. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2011;2:54. doi: 10.3389/fimmu.2011.00054.
4. Borte S, von Dobeln U, Hammarstrom L. Guidelines for newborn screening of primary immunodeficiency diseases. Curr Opin Hematol. 2013;20(1):48-54. doi: 10.1097/MOH.0b013e32835a9130.
5. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94-100.
6. Yong PL, Boyle J, Ballow M, Boyle M, Berger M, Bleesing J, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol. 2010;135(2):255-63. doi: 10.1016/j.clim.2009.10.003.
7. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525-53. doi: 10.1016/j.jaci.2006.01.015.
8. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol. 2006;26(2):177-85. doi: 10.1007/s10875-006-9002-x.
9. Gardulf A, Hammarstrom L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338(8760):162-6.
10. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112(1):1-7. doi: 10.1016/j.clim.2004.02. 002.
11. Toubi E, Etzioni A. Intravenous immunoglobulin in immunodeficiency states: state of the art. Clin Rev Allergy Immunol. 2005;29(3):167-72. doi: 10.1385/CRIAI:29:3:167.
12. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008;28(4):779-802, viii. doi: 10.1016/j.iac.2008.07.002.
13. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26(3):265-73. doi: 10.1007/s10875-006-9021-7.
14. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2007;21(2):105-16.
15. Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345(8946):365-9.
16. Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65-72. doi: 10.1007/s10875-006-8905-x.
17. Fasth A, Nystrom J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007;96(10):1474-8. doi: 10.1111/j.1651-2227.2007.00485.x.
18. Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Bock A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114(4):936-42. doi: 10.1016/j.jaci.2004.06.053.
19. Gardulf A, Borte M, Ochs HD, Nicolay U. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol. 2008;126(1):81-8. doi: 10.1016/j.clim.2007.06.009.
20. Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics. 1996;98(6 Pt 1):1127-31.
21. Bhole MV, Burton J, Chapel HM. Self-infusion programmes for immunoglobulin replacement at home: feasibility, safety and efficacy. Immunol Allergy Clin North Am. 2008;28(4):821-32, ix. doi: 10.1016/j.iac.2008.06.005.
22. Borte M, Bernatowska E, Ochs HD, Roifman CM. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clin Exp Immunol. 2011;164(3):357-64. doi: 10.1111/j.1365-2249.2011.04376.x.
23. Maroto Hernando M, Soler Palacin P, Martin Nalda N, Oliveras Arenas M, Espanol Boren T, Figueras Nadal C. Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain. An Pediatr (Barc). 2009;70(2):111-9. doi: 10.1016/j.anpedi.2008.11.011.
24. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999;93(3):190-7.
25. Sorensen RU, Leiva LE, Javier 3rd FC, Sacerdote DM, Bradford N, Butler B, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol. 1998;102(2):215-21.
26. FDA. Safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Guidance for industry; 2008. FDA. 2008. http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm072130.htm. Accessed 5 Sept 2012.
27. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79(1):48-51.
28. Hagan JB, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5):734-45. doi: 10.1007/s10875-010-9423-4.
29. Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol. 1994;14(2):90-7.
30. Jolles S, Bernatowska E, de Gracia J, Borte M, Cristea V, Peter HH, et al. Efficacy and safety of Hizentra((R)) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol. 2011;141(1):90-102. doi: 10.1016/j.clim.2011.06.002.
31. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2008;28(2):413-37, x. doi: 10.1016/j.iac.2008.01.008.
32. Haddad E, Berger M, Wang EC, Jones CA, Bexon M, Baggish JS. Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency. J Clin Immunol. 2012;32(2):281-9. doi: 10.1007/s10875-011- 9631-6.